New Stem Cell State

Through cellular reprogramming, researchers have produced a novel pluripotent mouse stem cell in vitro.

Written byAnna Azvolinsky
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

F-class cellsLUNENFELD-TANENBAUM RESEARCH INSTITUTE/PETER D. TONGEResearchers from Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute and their international colleagues have uncovered a new type of pluripotent mouse stem cell—the “F-class” cell—through use of a somatic cell reprogramming approach. An F-class cell is able to differentiate into all three embryonic precursor tissues, yet is phenotypically and molecularly different from previously characterized induced pluripotent stem cells (iPSCs) made from somatic cells. These F-class cells proliferate more quickly than other stem cells in vitro, and are characteristically low-adhesion, giving them a fuzzy appearance. The results are published today (December 10) in Nature.

“What I find particularly exciting is that this opens up the idea that there may be different kinds of pluripotent stem cells,” said Paul Knoepfler, a stem cell biologist at the University of California, Davis, who was not involved in the work.

Juan Carlos Izpisua Belmonte, a developmental biologist at the Salk Institute for Biological Studies in La Jolla, California, who penned an accompanying editorial, agreed. “These studies and our understanding of embryo development teach us that we shouldn’t assume the known pluripotent stem cells represent the whole spectrum of pluripotency. Rather, there exists a multitude of pluripotent states or novel pluripotent states can be engineered through cellular reprograming,” Belmonte told The Scientist in an e-mail.

A second Nature paper published today provides a detailed ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • head shot of blond woman wearing glasses

    Anna Azvolinsky received a PhD in molecular biology in November 2008 from Princeton University. Her graduate research focused on a genome-wide analyses of genomic integrity and DNA replication. She did a one-year post-doctoral fellowship at Memorial Sloan Kettering Cancer Center in New York City and then left academia to pursue science writing. She has been a freelance science writer since 2012, based in New York City.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies